# Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma

> **NCT02743819** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Chicago** · enrollment: 70 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT02743819
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-06-28
- **Primary completion:** 2022-06-01
- **Final completion:** 2026-06
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2025-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02743819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02743819, "Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02743819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*